6-(2,5-Dichlorophenyl)-1,2,4-triazine-3,5-diamine | 77668-43-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-(2,5-Dichlorophenyl)-1,2,4-triazine-3,5-diamine
• CAS: 77668-43-0
• 化学式: C₉H₇Cl₂N₅
• 分子量: 256.09
• InChiKey: QPXGLZOHUMHCAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  90.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Medical Use of Triazine Derivatives
  申请人：Leach Michael

  公开号：US20090291954A1

  公开（公告）日：2009-11-26

  Compounds of formula (I) especially where R 1 is an optionally substituted alkyl, aralkyl or heterocyclyl-alkyl group, are shown to have activity as sodium channel blockers or as antifolates. Some novel compounds where R 1 is an aralkyl or hetero-cyclyl-alkyl are disclosed.

  化合物的公式(I)，特别是其中R1为可选取代的烷基、芳基烷基或杂环基烷基的化合物，具有作为钠通道阻滞剂或抗叶酸剂的活性。其中一些新颖的化合物，其中R1为芳基烷基或杂环基烷基，已被披露。
• Oligomer-Containing Substituted Aromatic Triazine Compounds
  申请人：Riggs-Sauthier Jennifer

  公开号：US20120122871A1

  公开（公告）日：2012-05-17

  The invention relates to (among other things) oligomer-containing substituted aromatic triazine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.

  本发明涉及（除其他事项外）含寡聚物的取代芳香三嗪化合物。本发明的化合物，当通过任何一种给药途径给予时，表现出与缺乏寡聚物的相应化合物相比更多的优点。
• NEW MEDICAL USE OF TRIAZINE DERIVATIVES
  申请人：LEACH Michael

  公开号：US20130005732A1

  公开（公告）日：2013-01-03

  Compounds of formula (I): especially where R 1 is an optionally substituted alkyl, aralkyl or heterocyclyl-alkyl group, are shown to have activity as sodium channel blockers or as antifolates. Some novel compounds where R 1 is an aralkyl or heterocyclyl-alkyl are disclosed.

  化合物的公式(I)：特别是其中R1是可选取的取代基的烷基，芳基烷基或杂环基-烷基团，已被证明具有作为钠通道阻滞剂或抗叶酸活性。披露了一些新的化合物，其中R1是芳基烷基或杂环基-烷基。
• 1,2,4-Triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0021121A1

  公开（公告）日：1981-01-07

  The present invention provides compounds of the formula (III): or an acid addition salt thereof, wherein R6 is chlorine, bromine, iodine, C1-4alkyl or trifluoromethyl, R7 is hydrogen, halogen, C1-4alkyl or trifluoromethyl or R6 and R7 form a -CH=CH-CH=CH- group optionally substituted by a halogen atom or a C1-4alkyl or trifluoromethyl group, R8 is hydrogen, halogen, C1-4alkyl or trifluoromethyl, R9 is hydrogen, halogen, C1-4alkyl or trifluoromethyl, R10 is hydrogen, methyl or fluorine and R" is amino, C1-4acylamino or di-substituted aminomethyleneamino provided that, at most, only two of R7―R10 are other than hydrogen and that R7―R10 are not all hydrogen when R6 is chlorine. Also provided are pharmaceutical compositions containing compounds of the formula (III), the first medical use of compounds of the formula (III), a process for preparing such compounds and intermediates through which this process proceeds.

  本发明提供了式(III)化合物： 或其酸加成盐，其中R6是氯、溴、碘、C1-4烷基或三氟甲基，R7是氢、卤素、C1-4烷基或三氟甲基或R6和R7形成任选被卤原子或C1-4烷基或三氟甲基取代的-CH=CH-CH=CH-基团，R8是氢、卤素、C1-4烷基或三氟甲基，R9是氢、卤素、C1-4烷基或三氟甲基，R10是氢、甲基或氟，R "是氨基、C1-4酰氨基或二取代氨基亚甲基氨基，条件是R7-R10中最多只有两个不是氢，并且当R6是氯时，R7-R10不全是氢。本发明还提供了含有式（III）化合物的药物组合物、式（III）化合物的第一种医疗用途、制备此类化合物的工艺以及该工艺所经过的中间体。
• Triazine compounds having cardiovascular activity
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0142306A2

  公开（公告）日：1985-05-22

  Compounds of Formula I are novel and useful as cardiovascular agents, particularly anti-arrhythmic agents: or the 5-amino tautomerthereof or a salt of either, wherein R1 is C1-10alkyl, C2-loalkenyl, C2-loalkynyl or C3-iocycloalkyl, any of which is optionally substituted, and R2 to R6 are independently selected from hydrogen, halogen atom, C1-6alkyl, alkenyl or alkynyl (all optionally substituted by one or more of halogen, hydroxy and aryl), amino, mono- or di-substituted amino, alkoxy (optionally substituted by one or more of halogen, hydroxy and aryl), alkenyloxy, acyl, acyloxy, cyano, nitro, aryl and alkylthio groups or any adjacent two of R2 to R6 are linked to form a (-CH=CH-CH=CH-) group.

  式 I 的化合物是新颖且有用的心血管药物，特别是抗心律失常药物： 或其 5-氨基同系物或二者的盐，其中 R1 是 C1-10 烷基、C2-烯基、C2-炔基或 C3-环烷基，其中任何一个均可选被取代，R2 至 R6 独立选自氢、卤素原子、C1-6 烷基、烯基或炔基（均可选被卤素、羟基和芳基中的一个或多个取代）、氨基、一或二取代氨基、烷氧基（可选被卤素、羟基和芳基中的一个或多个取代）、或二取代的氨基、烷氧基（任选被卤素、羟基和芳基中的一个或多个取代）、烯氧基、酰基、酰氧基、氰基、硝基、芳基和烷硫基，或 R2 至 R6 的任意相邻两个连接形成 (-CH=CH-CH=CH-) 基团。